Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Drug Analysis: V180 - More Compact Dosing Schedule Could Make It a More Attractive Alternative to Dengvaxia - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Drug Analysis: V180" drug pipelines has been added to ResearchAndMarkets.com's offering.

Merck & Co's adjuvanted, tetravalent subunit vaccine V180 comprises truncated forms of envelope proteins (DEN-80E), derived from strains of all four dengue virus serotypes (DEN-1 strain 258848, DEN-2 strain PR159 S1, DEN-3 strain CH53489, and DEN-4 strain H241). The DEN-80E subunits are expressed from plasmids in the Drosophila S2 cell expression system and are then formulated with either ISCOMATRIX (saponin, cholesterol, and phospholipid adjuvant; CSL) or Alhydrogel (aluminium hydroxide gel adjuvant; Brenntag Nordic).

V180 is currently in Phase I development in the US and Australia only, but Merck & Co is likely to target the same dengue-endemic Asia-Pacific and Latin American markets as Sanofi Pasteur and Takeda.

V180's more compact dosing schedule could make it a more attractive alternative to Dengvaxia, particularly for travelers, although its current three-dose schedule could still be improved upon to reduce the risk of non-compliance. It is believed that V180 would achieve its greatest commercial potential as part of a heterologous prime-boost strategy with TetraVax-DV (tetravalent live-attenuated chimeric vaccine; Biological E/Panacea Biotec/Butantan Institute/Merck & Co/Vabiotech), which the company has in-licensed from the US National Institutes of Health, potentially simplifying the vaccination schedule to just two doses. Such a strategy would be attractive for routine immunization programs and for the traveler/military segments, but V180 will likely face competition from GlaxoSmithKline, which is currently pursuing a similar strategy with DPIV (adjuvanted, tetravalent formalin-inactivated vaccine). However, Merck & Co is yet to launch Phase II trials, and since there has been no progress in development since Q4 2016, the future of V180 is unclear.

Key Topics Covered:

Product Profiles

V180: Dengue vaccines

List of Figures

Figure 1: V180 for dengue fever - SWOT analysis

List of Tables

Table 1: V180 drug profile

Table 2: V180 Phase I data in dengue fever

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jww7gn/global_drug?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005819/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.